News
28m
FirstSportz on MSNMischa Zverev Shockingly Refuses to Give Sympathy to Brother Alexander Zverev after his Admission on Mental Struggles at WimbledonMischa Zverev showed little sympathy after his brother Alexander Zverev‘s emotional remarks following his early Wimbledon ...
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results